Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-23
2010-12-07
Schultz, J D (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S325000, C435S375000
Reexamination Certificate
active
07846910
ABSTRACT:
The present invention relates to a pharmaceutical composition for the prevention and treatment for β-amyloid (Aβ) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades Aβ monomer and oligomer but also degrades soluble Aβ and insoluble Aβ, particularly aggregated Aβ, so that it can prevent the accumulation of Aβ in brain or reduce the accumulation, making it an excellent candidate for the therapeutic agent for Alzheimer's disease and Down's syndrome.
REFERENCES:
patent: WO 95/09838 (1995-04-01), None
patent: WO 01/39796 (2001-06-01), None
patent: WO 03/055910 (2003-07-01), None
SP database Acc. No. Q4609.1 from Bzdega et al, Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem. Dec. 1997;69(6):2270-7. Alignment with SEQ ID No. 2.
Bzdega et al, Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem. Dec. 1997;69(6):2270-7.
Patil et al., The AAPS Journal 2005; AAPS J. Apr. 8, 2005;7(1):E61-77.
Pahnke et al., Neuroscience and Biobehavioral Reviews 33 (2009) 1099-1108.
Sacha et al. Neuroscience 144 (2007) 1361-1372.
Devlin et al., “Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia,”Human Molecular Genetic, 9(19): 2837-2844 (2000).
Matsumoto et al., “Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids,”Neuroscience Research, 39(3): 313-317 (2001). Abstract Only.
Matsumoto et al., “Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons,”European Journal of Neuroscience, 13(9): 1653-1657 (2001).
Papp et al., “Expression and distribution of carboxypeptidase B in the hippocampia subregions of normal and Alzheimer's disease brain,”Acta Biol Hung, 54(1): 55-62 (2003). Abstract Only.
Ahn Sang-Mee
Chae San Sook
Seo So Young
Klarquist & Sparkman, LLP
Korea Center for Disease Control and Prevention
Schultz J D
LandOfFree
Pharmaceutical composition, composition for screening... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, composition for screening..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition, composition for screening... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189928